PASADENA, Calif.--(BUSINESS WIRE)--
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that
Arrowhead's president and chief executive officer Christopher Anzalone,
Ph.D., will present a corporate overview at the Jefferies 2015
Healthcare Conference on June 3, 2015 at 10:00 a.m. EDT.
Investors may access live and archived versions of the audio webcast of
this presentation on the Events and Presentations page of the Company's
website at http://ir.arrowheadresearch.com/events.cfm.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
Dynamic Polyconjugate delivery platform to develop targeted drugs based
on the RNA interference mechanism that efficiently silences
disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic
hepatitis B virus and ARC-AAT for liver disease associated with Alpha-1
antitrypsin deficiency.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter @ArrowRes.
To be added to the Company's email list and receive news directly,
please visit http://ir.arrowheadresearch.com/alerts.cfm.
Source: Arrowhead Research Corporation
View source version on businesswire.com: http://www.businesswire.com/news/home/20150527005435/en/
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
Investor
Relations:
The Trout Group
Todd James
646-378-2926
ir@arrowres.com
or
Media:
Russo
Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com
Source: Arrowhead Research Corporation
News Provided by Acquire Media
